5 April 2024 – Since 1 January 2024, a 40 percent higher retention fee is applicable to certain medicines. The increased retention fee applies in particular to original and reference preparations if they are too expensive compared to an equivalent generic or biosimilar product. The aim of the measure is to promote generic and biosimilar products.

For more information, see here.